November 2023

Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ — The U.S. Fo

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: